Related Experiment Videos
[Effects of interferon on various malignancies]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 1, 1984
Summary
This review covers clinical studies of interferons, including human lymphoblastoid interferon (HLBI), human fibroblast interferon (HuIFN-beta), and recombinant leukocyte A interferon (r-IFN-alpha A), showing antitumor effects against various cancers.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Context:
- Interferons are a class of proteins with diverse biological activities.
- Clinical applications of interferons in cancer treatment have been explored globally.
- Japan has a history of investigating various interferon types for therapeutic use.
Purpose:
- To provide an overview of clinical studies on different types of interferons.
- To summarize the observed antitumor effects of interferons in various malignancies.
- To document the adverse reactions associated with interferon therapy.
Summary:
- Clinical trials in Japan evaluated human lymphoblastoid interferon (HLBI), human fibroblast interferon (HuIFN-beta), and recombinant leukocyte A interferon (r-IFN-alpha A).
- These interferons demonstrated antitumor activity against a range of cancers, including lymphoma, myeloma, renal cell carcinoma, leukemias, brain tumors, melanoma, and mycosis fungoides.
- Common adverse reactions included fever, fatigue, leukopenia, thrombocytopenia, and abnormal liver function tests.
Impact:
- Highlights the therapeutic potential of interferons in treating diverse malignancies.
- Provides insights into the efficacy and safety profile of interferons in clinical settings.
- Contributes to the understanding of interferon-based cancer therapies.